Ignite Creation Date:
2024-05-05 @ 11:34 PM
Last Modification Date:
2024-10-26 @ 10:36 AM
Study NCT ID:
NCT01363934
Status:
COMPLETED
Last Update Posted:
2012-07-19
First Post:
2011-05-31
Brief Title:
To Evaluate the Safety Tolerability and PharmacokineticsPharmacodynamics of Erythropoietin
Sponsor:
Green Cross Corporation
Organization:
GC Biopharma Corp
Study Overview
Official Title:
A Dose-Block Randomized Double-blind Placebo Controlled Open-label Active Controlled Dose-escalation Study to Investigate the Safety Tolerability and PharmacokineticsPharmacodynamics of GC1113 After Single IntravenousSubcutaneous Administration in Healthy Male Subjects
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Dose-Block Randomized Double-blind Placebo controlled Open-label Active controlled Dose-escalation Study to investigate the safety tolerability and PharmacokineticsPharmacodynamics of GC1113 after Single IntravenousSubcutaneous Administration in Healthy Male Subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None